Predicting high risk of exacerbations in bronchiectasis: the E-FACED score

Area of Science:

• Pulmonary Medicine
• Clinical Prognostics
• Epidemiology

Background:

• The FACED score is a prognostic tool for bronchiectasis but omits exacerbation frequency.
• Exacerbations significantly impact bronchiectasis progression and patient outcomes.

Purpose of the Study:

• To construct and externally validate the E-FACED score, incorporating exacerbation severity and frequency.
• To assess the E-FACED score's predictive capacity for exacerbations and mortality in bronchiectasis patients.

Main Methods:

• The E-FACED score was developed using existing cohort data and validated across six international cohorts.
• Statistical analysis determined the optimal weight for exacerbation frequency (≥2 exacerbations/year) within the FACED framework.
• The predictive performance of E-FACED was compared against the original FACED score for exacerbations and mortality.

Main Results:

• The E-FACED score, with a maximum of nine points, demonstrated superior prediction of exacerbations (AUC 0.82-0.87) compared to FACED (AUC 0.72-0.78).
• E-FACED showed excellent prognostic capacity for all-cause and respiratory mortality (AUC 0.86-0.87), comparable to the FACED score.
• External validation confirmed the E-FACED score's robust predictive capabilities across diverse patient cohorts.

Conclusions:

• The E-FACED score significantly enhances the prediction of future yearly exacerbations in bronchiectasis.
• It retains the simplicity and prognostic value of the FACED score for mortality prediction.
• E-FACED offers a more comprehensive prognostic assessment for bronchiectasis management.